Black Diamond Therapeutic Analyst Ratings
Black Diamond Therapeutic Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/22/2023 | 411.63% | HC Wainwright & Co. | → $11 | Reiterates | Buy → Buy |
| 09/12/2023 | 365.12% | Wedbush | → $10 | Reiterates | Outperform → Outperform |
| 07/14/2023 | 411.63% | Piper Sandler | → $11 | Initiates Coverage On | → Overweight |
| 06/30/2023 | 365.12% | Stifel | $2 → $10 | Upgrades | Hold → Buy |
| 06/28/2023 | 411.63% | HC Wainwright & Co. | → $11 | Upgrades | Neutral → Buy |
| 06/27/2023 | -6.98% | Stifel | → $2 | Reiterates | Hold → Hold |
| 06/27/2023 | 365.12% | Wedbush | $3 → $10 | Upgrades | Neutral → Outperform |
| 05/10/2023 | 39.53% | Wedbush | → $3 | Reiterates | → Neutral |
| 03/29/2022 | — | Wedbush | Downgrades | Outperform → Neutral | |
| 03/22/2022 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 03/18/2022 | 86.05% | Stifel | $10 → $4 | Maintains | Hold |
| 09/30/2021 | 365.12% | Stifel | → $10 | Initiates Coverage On | → Hold |
| 01/07/2021 | — | Wedbush | Initiates Coverage On | → Outperform | |
| 11/24/2020 | 2597.67% | Berenberg | → $58 | Initiates Coverage On | → Buy |
| 05/04/2020 | 2365.12% | HC Wainwright & Co. | → $53 | Initiates Coverage On | → Buy |
| 02/24/2020 | 2086.05% | Jefferies | → $47 | Initiates Coverage On | → Buy |
| 02/24/2020 | 2225.58% | Canaccord Genuity | → $50 | Initiates Coverage On | → Buy |
| 02/24/2020 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 02/24/2020 | 1853.49% | JP Morgan | → $42 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/22/2023 | 411.63% | HC Wainwright & Co. | → 11 美元 | 重申 | 購買 → 購買 |
| 09/12/2023 | 365.12% | Wedbush | → 10 美元 | 重申 | 跑贏大盤 → 跑贏大盤 |
| 07/14/2023 | 411.63% | 派珀·桑德勒 | → 11 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 06/30/2023 | 365.12% | Stifel | 2 美元 → 10 美元 | 升級 | 持有 → 買入 |
| 06/28/2023 | 411.63% | HC Wainwright & Co. | → 11 美元 | 升級 | 中性 → 買入 |
| 06/27/2023 | -6.98% | Stifel | → 2 美元 | 重申 | 按住 → 按住 |
| 06/27/2023 | 365.12% | Wedbush | 3 美元 → 10 美元 | 升級 | 中性 → 跑贏大盤 |
| 05/10/2023 | 39.53% | Wedbush | → 3 美元 | 重申 | → 中立 |
| 03/29/2022 | — | Wedbush | 降級 | 跑贏大盤 → 中性 | |
| 03/22/2022 | — | HC Wainwright & Co. | 降級 | 買入 → 中性 | |
| 03/18/2022 | 86.05% | Stifel | 10 美元 → 4 美元 | 維護 | 保持 |
| 09/30/2021 | 365.12% | Stifel | → 10 美元 | 啓動覆蓋範圍開啓 | → 按住 |
| 01/07/2021 | — | Wedbush | 啓動覆蓋範圍開啓 | → 跑贏大盤 | |
| 11/24/2020 | 2597.67% | 貝倫貝格 | → 58 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 05/04/2020 | 2365.12% | HC Wainwright & Co. | → 53 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2020 年 2 月 24 日 | 2086.05% | 傑富瑞集團 | → 47 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2020 年 2 月 24 日 | 2225.58% | Canaccord Genu | → 50 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2020 年 2 月 24 日 | — | Cowen & Co. | 啓動覆蓋範圍開啓 | → 跑贏大盤 | |
| 2020 年 2 月 24 日 | 1853.49% | 摩根大通 | → 42 美元 | 啓動覆蓋範圍開啓 | → 超重 |
What is the target price for Black Diamond Therapeutic (BDTX)?
黑鑽療法（BDTX）的目標價格是多少？
The latest price target for Black Diamond Therapeutic (NASDAQ: BDTX) was reported by HC Wainwright & Co. on November 22, 2023. The analyst firm set a price target for $11.00 expecting BDTX to rise to within 12 months (a possible 411.63% upside). 8 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年11月22日公佈了黑鑽療法（納斯達克股票代碼：BDTX）的最新目標股價。該分析公司將目標股價定爲11.00美元，預計BDTX將在12個月內升至12個月內（可能上漲411.63％）。去年有8家分析公司公佈了評級。
What is the most recent analyst rating for Black Diamond Therapeutic (BDTX)?
分析師對黑鑽療法（BDTX）的最新評級是多少？
The latest analyst rating for Black Diamond Therapeutic (NASDAQ: BDTX) was provided by HC Wainwright & Co., and Black Diamond Therapeutic reiterated their buy rating.
HC Wainwright & Co. 對黑鑽療法（納斯達克股票代碼：BDTX）的最新分析師評級由HC Wainwright & Co. 提供，黑鑽治療重申了其買入評級。
When is the next analyst rating going to be posted or updated for Black Diamond Therapeutic (BDTX)?
下一次分析師對黑鑽療法（BDTX）的評級將在何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Black Diamond Therapeutic, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Black Diamond Therapeutic was filed on November 22, 2023 so you should expect the next rating to be made available sometime around November 22, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Black Diamond Therapical的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。黑鑽療法的最新評級是在2023年11月22日公佈的，因此您應該預計下一個評級將在2024年11月22日左右公佈。
Is the Analyst Rating Black Diamond Therapeutic (BDTX) correct?
分析師對黑鑽療法（BDTX）的評級是否正確？
While ratings are subjective and will change, the latest Black Diamond Therapeutic (BDTX) rating was a reiterated with a price target of $0.00 to $11.00. The current price Black Diamond Therapeutic (BDTX) is trading at is $2.15, which is within the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的黑鑽療法（BDTX）評級得到了重申，目標股價爲0.00美元至11.00美元。黑鑽療法（BDTX）的當前交易價格爲2.15美元，在分析師的預測區間內。
譯文內容由第三人軟體翻譯。